Drug intelligence / Profile preview

Gelsectan

Development stage
Phase 4
Lead developer
Devintec
Modality
Peptides
Administration
Oral
01

Overview

Gelsectan is a multi-ingredient therapeutic product, classified as a medical device, designed to restore intestinal barrier function and protect the gut mucosa in patients with Irritable Bowel Syndrome (IBS), particularly the diarrhea-predominant phenotype (IBS-D). It contains xyloglucan, a tamarind-derived polysaccharide that acts as a mucoprotectant by forming a physical film over the intestinal epithelium to prevent the adhesion of pathogens and toxins. This effect is reinforced by pea protein and grape seed extract, which help stabilize the protective barrier. Additionally, the formulation includes xylo-oligosaccharides (XOS), which serve as a prebiotic to promote the growth of beneficial gut bacteria. By reducing mucosal permeability and inflammation, Gelsectan aims to alleviate chronic diarrhea, abdominal pain, and bloating associated with IBS and post-infectious IBS.

Brand names
Gelsectan
Other names
Xyloglucan + pea protein + grape seed extract + xylo-oligosaccharides

Beyond the preview

Go deeper on Gelsectan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gelsectan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call